New HIV Drug Could Revolutionize Prevention at Just $40 Annually

Researchers argue that generic production of Lenacapavir could drastically reduce costs and control HIV transmission globally.

Lenacapavir, developed by Gilead, shows 100% effectiveness in preventing HIV in early trials.
The drug, currently priced at over $40,000 annually, could be produced for $40 with generic licensing.
Administered twice yearly, Lenacapavir offers a simpler alternative to daily HIV prevention pills.
UNAIDS and researchers urge Gilead to allow generic manufacturing to make the drug accessible worldwide.
Gilead is awaiting further clinical trial data but promises a strategy for broad, sustainable access.